Sterling Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
Other funds holding GLUE
BBA
Sterling Capital Management's GLUE Position: Q3 2026 in Review
Sterling Capital Management increased its Monte Rosa Therapeutics (GLUE) stake by 842% in Q3 2026, buying an estimated $37.5K and bringing the position to 2,450 shares worth $29.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2005.
Sterling Capital Management first reported a position in GLUE in Q3 2024 and has held it in 9 quarters since. The position peaked at $149K in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.
- Sterling Capital Management held 2,450 shares of Monte Rosa Therapeutics worth $29.2K as of Q3 2026.
- Sterling Capital Management bought 2,190 Monte Rosa Therapeutics shares in Q3 2026, an estimated $37.5K.
- Monte Rosa Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2005 holding.
- Sterling Capital Management first reported a position in Monte Rosa Therapeutics in Q3 2024 and has held it in 9 quarters since.
- Sterling Capital Management's Monte Rosa Therapeutics position peaked at $149K in Q4 2025.
- 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.
Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.